Search

Inauguration of new integrated Asian Veterinary R&D Center in China

Boehringer Ingelheim confirms its commitment to growth in China with the investment of 19 million euros in its new integrated Asian Veterinary Research & Development Center

Inauguration of new global center for veterinary vaccine R&D

Inauguration of a new global hi-tech centre for biological research and development in Lyon.

New production center for Veterinary Public Health

Boehringer Ingelheim invests more than €200 million to establish a strategic production center for Veterinary Public Health in Lyon, France.

Launch of first veterinary vaccines produced in China

Swine vaccine Ingelvac PRRS MLV, produced by Boheringer Ingelheim veterinary vaccine manufacturing plant in Taizhou is now officially supplied to the China market.

Groundbeaking of vaccine production center in France

Boehringer Ingelheim breaks ground on its strategic vaccine production center for veterinary public health

Boehringer Ingelheim opens Health Management Centre in China

Boehringer Ingelheim opens Health Management Centre in China The new Health Management Centre integrates animal disease and health diagnostics as well as monitoring tools The centre further strengthens the company’s ability to provide services along the f

World Veterinary Day aspects veterinary profession

• World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated.

Partnership to further develop pet market in China

Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes

GastroGard the first imported equine drug in China

GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.

biopharmaceuticals-in-china

Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.

New exchange platform with Harbin Research Institute

Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform

Boehringer biopharmaceuticals China receives approval supply EU and US

Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets

Veterinary oncology experts meet in Germany

Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany

Kicking off 2024 with five new R&D partnerships

We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.

Launch of BVDzero scholarship for veterinary students

Launch of BVDzero scholarship for veterinary students globally

LastMile increases access to veterinary care in Africa

Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine

Classical Swine Fever live vaccine approved in China

Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved

DiaTEC new purification technology Ingelvac CircoFLEX

Boehringer Ingelheim introduces DiaTEC, a new and proprietary purification technology for Ingelvac CircoFLEX®

Equestrian sports horse health awareness Alex Hua Tian

Together with Olympian trailblazer and eventer Alex Hua Tian, we educate about equine health in China.

biologicals-development-center

Europe’s largest biotechnology center in Biberach, Germany is the home to three development units.